Barbara Burton, MD, Professor of Pediatrics at Northwestern University Feinberg School of Medicine, highlights the latest research about Mucopolysaccharidosis type II (MPS II; Hunter syndrome) presented at WORLDSymposium 2022. This free CME program provides expert analysis on the clinical relevance of this research for the care team and help them care for the patients they may encounter with this rare condition.
MPS II or Hunter syndrome is a rare, progressive lysosomal disease caused by deficient activity of iduronate-2-sulfatase, attributable to pathogenic variants of the iduronate-2-sulfatase gene (IDS). Course facial features and skeletal irregularities are the dominant symptoms of the periphery but of great concern is the central symptoms (cognitive decline, seizures) that occur in the more severe cases. Current therapies options include enzyme replace therapy but newer treatment options are in development, including treatments that may address the central symptoms.
To access this free CME program, learn more about MPS II, and improve the way you interact with your patients with this rare condition, visit https://checkrare.com/learning/p-mps-ii-research-highlights-worldsymposium-2022/
Supported by an educational grant from Takeda Pharmaceuticals U.S.A. Inc.